演題速報 デイリーランキング
このサイトは医療関係者の方々を対象に作成しています。
必ずご利用規約に同意の上、ご利用ください。記事内容で取り上げた薬剤の効能・効果および用法・用量には、日本国内で承認されている内容と異なるものが、多分に含まれていますのでご注意ください。
6月1日 演題レポート
Abstract #3512
Validation of the 12-gene colon cancer Recurrence Score result in NSABP C-07 as a predictor of recurrence in stage II and III colon cancer patients treated with 5FU/LV (5FU) and 5FU/LV + oxaliplatin (5FU+Ox)
Michael J O’Connell, et al.
Epiregulin (EREG) and Amphiregulin (AREG) gene expression predict response to cetuximab (cet) therapy in combination with oxaliplatin (Ox) and 5FU in first-line treatment of advanced colorectal cancer (aCRC) - Results from the MRC COIN trial.
Richard A. Adams, et al.
Abstract #3519
Ligand expression of the EGFR ligands amphiregulin, epiregulin, and amplification of the EGFR gene to predict for treatment efficacy in KRAS wild-type mCRC patients treated with cetuximab plus CAPIRI and CAPOX: Analysis of the randomized AIO CRC-0104 trial.
Sebastian Stintzing, et al.
Abstract #3522
Impact of age and medical comorbidity (MC) for oxaliplatin on adjuvant treatment outcomes for stage III colon cancer (CC): a pooled analysis of individual patient data from four randomized controlled trials.
Daniel G. Haller, et al.
Abstract #3523
Effect of oxaliplatin based adjuvant therapy on post-relapse survival (PRS) in patients with stage III colon cancer: a pooled analysis of individual patient data from four randomized controlled trials.
Christopher Twelves, et al.